Happy to remain patient21 Jun 2021 13:20
15% down after a reasonable presentation and an RNS confirming a named distributor ? Go figure.
I realise there are many, both impatient and mischievous, individuals demanding immediate confirmation of order volumes and prices but I would have expected the wider market to take a longer view.
Current cash situation confirmed as sufficient to support ongoing R&D until 2023.
AVA6000 trial commencing in July.
A validated, CE marker LFT with excellent performance characteristics now exists.
Additional overseas manufacturing has been sourced which raises capacity beyond the domestic limit of 30million per month.
Avacta’s margin on a test has been quantified as between 1-2 euros.
Demand outstrips supply so as orders arrive if we reach maximum manufacturing capacity that’s over £1.2 billion per annum.
Orders will be confirmed in coming weeks.